



LAMPIRE
BIOLOGICAL LABORATORIES

BOVINE
ULTRA-LONG CDR3 PICOBODIES



BOVINE ULTRA-LONG CDR3 PICOBODIES

Explore the forefront of antibody research with monoclonal Bovine Ultra-long CDR3 Picobodies. Aligned with our commitment to scientific advancement, we introduce an opportunity to investigate Bovine Picobodies, incorporating "Single Bcell Sorting" and Directed Sequencing of ultralong-CDR3s.

What sets Bovine Picobodies apart?

These binding domains, sourced exclusively from Bovines, exhibit compactness and stability. With a small size ranging from 3 to 5 kiloDaltons (kDa), they mark an advancement in antibody technology. Derived from a specialized subset of Bovine ultralong-CDR3-containing antibodies, Picobodies offer potential for targeted therapy development.

Numerous possibilities

While in the nascent stages of preclinical development, picobody-derived recombinant antibodies, can be formatted into "knobbodies" and bispecific antibodies, and exhibit novel efficacy in binding viral and cancer target epitopes. This heralds a new era of precision medicine, where previously inaccessible targets become attainable.

Join us at the forefront of antibody innovation with LAMPIRE's Bovine Bcell technology. Explore the potential of Picobodies. Contact us today (215) 795-2838 / sales@lampire.com for more information, or a free technical consultation.

SOCIAL MEDIA

Subscribe, Like, Comment



CONTACT US

(e) LAMPIRE@LAMPIRE.COM
(w) WWW.LAMPIRE.COM
(p) (215) 795-2838
(f) (215) 795-0237

APPEARANCE



Düsseldorf, Germany
Location: Hall 1, Booth #B44